Hetal Marble

Dr. Hetal Marble is Head of Commercial for Immuto Scientific, a boutique CRO focused on protein structural characterization and drug discovery.

Dr. Marble has had varied and extensive experience leading life science businesses. She led diagnostic product management at Quanterix Corporation, where she launched Quanterix’s first diagnostic test for Alzheimer’s disease and directed product strategy and go-to-market for all clinical diagnostic and research services products. She also led companion diagnostics and biomarker development for the Center for Integrated Diagnostics at MGH where she grew the division’s in-house CRO into a multi-million dollar enterprise by translating novel technologies into clinical practice and leading precision biomarker strategies for clinical trials. Prior to her work at MGH, Hetal worked in business development, alliance management, and strategic product marketing for both Promega Corporation and Pall Biotech (a Danaher company), managing and growing burgeoning commercial territories into millions of dollars in revenue.

Hetal is foundationally an experienced research scientist – she received her Ph.D. at Brown University, where her graduate work focused on the development of biomarkers for lineage-specific stem cell differentiation - she is the holder of two U.S. patents emerging from that work. Hetal is active in the scientific community; she is the elected Chair of diversity, Equity, and Inclusion for the Association for Molecular Pathology(AMP); she is a member of the 2022 Women in Bio (WiB) cohort of Emerging Executives; she served on the Pathology Informatics Collaborative Community(PIcc), a collaborative community of the US Food and Drug Administration; and she is a contributing author on precision medicine for the book Taking Care of you, a book on women’s health being published by the Mayo Clinic Press in October 2022.